<?xml version="1.0" encoding="UTF-8"?>
<p>The data on IFN-λ and respiratory infections may have important clinical and public health implications. The SARS-CoV-2 outbreak represents the third time in the 21st century that we have recognized a highly pathogenic coronavirus introduced into the human population and it is likely that there will be more [
 <xref rid="CIT0002" ref-type="bibr">2</xref>]. IFNs are broad antivirals whose effectiveness might be anticipated for such emerging epidemics. The adverse effects of type I IFNs may limit their use for widespread intervention, as is being proposed in the IFN-β plus ritonavir/lopinavir arm of the World Health Organization Solidarity trial [
 <xref rid="CIT0022" ref-type="bibr">22</xref>]; however, adverse effects are notably lower with pegylated IFN-λ1 [
 <xref rid="CIT0018" ref-type="bibr">18</xref>]. Pegylated IFN-λ1 might be deployed early in an outbreak, months or years before specific antivirals or vaccines can be developed and tested.
</p>
